Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  Merck & Co., Inc.    MRK

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets 

Merck & Co., Inc. : Merck On Track to File Application for Insomnia Drug This Year

share with twitter share with LinkedIn share with facebook
share via e-mail
0
06/13/2012 | 02:52pm CEST
   By Victoria Stilwell 
 

Merck & Co. (MRK) said it is on track to file a new drug application for its experimental insomnia medicine this year, making the drug one of six major filings planned for 2012 and 2013.

Data from a Phase 3 clinical trial showed Merck's insomnia drug suvorexant reduced the time it took patients to fall asleep and increased the time patients stayed asleep as early as the first night and at the three-month point compared with a placebo.

The drug met statistical significance on 15 out of 16 primary endpoints. The findings were to be presented at the Annual Meeting of the Associated Professional Sleep Societies.

Merck, like its rivals, has been cutting costs as part of an effort to soften the hit from increased generic competition. The company's top-selling allergy and asthma medication Singulair loses patent exclusivity in August and the ripple-effect from generic versions of rival Pfizer Inc.'s (PFE) cholesterol fighter Lipitor have contributed to a decline in sales of Merck's anticholesterol drug Vytorin.

Merck reported in April first-quarter earnings rose 67% as the drug maker's cost controls helped offset slower-than-expected sales growth.

Shares closed at $38.43 Tuesday and were inactive in premarket trade. The stock is up 8.8% in the past 12 months.

Write to Victoria Stilwell at Victoria.Stilwell@dowjones.com

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on MERCK & CO., INC.
03/27 Chinese drug approval boosts AstraZeneca's lung cancer hopes
03/25 Merck KGaA and Pfizer break into cancer immunotherapy
03/25 Pfizer, Merck KGaA score watershed FDA nod on cancer immunotherapy Bavencio
03/24 MERCK : European Medicines Agency’s CHMP Recommends Approval of Merck&rsqu..
03/23 MERCK : Findings from Merck & Company in the Area of Pharmaceutical Science Repo..
03/23 MERCK : New Human Papillomavirus Findings from Merck & Company Reported (Develop..
03/23 MERCK : New Hypoglycemia Study Findings Have Been Reported by Investigators at M..
03/23 MERCK : StayWell Earns Re-accreditation From the National Committee for Quality ..
03/22 MERCK ANIMAL HEALTH : Completes Acquisition of Vallée S.A.
03/17 MERCK : Keytruda`s head-to-head against Opdivo rockets meds to Nos. 2 and 3 in a..
More news
Sector news : Pharmaceuticals - NEC
06:51pDJSenator McCaskill Begins Probe of Prescription Opioid Marketing
06:27pDJREGENERON PHARMACEUTICALS : FDA Approves Regeneron and Sanofi's Dupixent for Ecz..
06:12pDJREGENERON PHARMACEUTICALS : FDA Approves Regeneron and Sanofi's Dupixent for Ecz..
08:48aDJDuPont, Dow Get EU Approval for Merger -- WSJ
03/27DJALEXION PHARMACEUTICALS : Names New CEO Following Internal Sales-Practice Probe
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
03/27 BIOLINERX : Expands Cancer Pipeline Significantly By Acquiring Novel Drug Candid..
03/27 Will Trump Send Drug Stocks Tumbling Again?
03/27 Alzheimer's Cure Is Science's Holy Grail - Will Biogen Find It?
03/26 PRO PORTFOLIO PROOF II : David Katz 'Safer' Value Portfolio Picks
03/26 With Healthcare Now Off Trump's Agenda, It's Time To Dive Into The Sector
Advertisement
Financials ($)
Sales 2017 39 720 M
EBIT 2017 13 557 M
Net income 2017 8 404 M
Debt 2017 4 038 M
Yield 2017 2,98%
P/E ratio 2017 19,64
P/E ratio 2018 16,31
EV / Sales 2017 4,47x
EV / Sales 2018 4,32x
Capitalization 173 493 M
More Financials
Chart MERCK & CO., INC.
Duration : Period :
Merck & Co., Inc. Technical Analysis Chart | MRK | US58933Y1055 | 4-Traders
Full-screen chart
Technical analysis trends MERCK & CO., INC.
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 22
Average target price 69,0 $
Spread / Average Target 9,2%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Kenneth C. Frazier Chairman, President & Chief Executive Officer
Robert M. Davis Chief Financial Officer & Executive Vice President
Clark Golestani Chief Information Officer & Executive VP
Thomas Henry Glocer Independent Director
Rochelle B. Lazarus Independent Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
MERCK & CO., INC.7.34%173 493
JOHNSON & JOHNSON8.91%341 030
ROCHE HOLDING LTD.8.73%220 248
PFIZER INC.5.23%203 546
NOVARTIS AG-0.47%195 735
SANOFI7.76%117 163
More Results